Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

被引：0
|
作者：
Lennart Tonneijck
Mark M. Smits
Marcel H. A. Muskiet
Trynke Hoekstra
Mark H. H. Kramer
A. H. Jan Danser
Michaela Diamant
Jaap A. Joles
Daniël H. van Raalte
机构：
[1] VU University Medical Center Amsterdam,Department of Internal Medicine/Diabetes Center
[2] VU University Amsterdam,Department of Health Sciences and the EMGO Institute for Health and Care Research
[3] VU University Medical Center,Department of Epidemiology and Biostatistics
[4] Erasmus University Medical Center,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[5] University Medical Center,Department of Nephrology and Hypertension
来源：
Diabetologia | 2016年 / 59卷
关键词：
Diabetes; Exenatide; Glomerular filtration rate; Glomerular hyperfiltration; GLP-1 receptor agonist; Glucagon-like peptide-1; Renal function; Renal haemodynamics; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1412 / 1421
页数：9
相关论文
共 50 条
  • [21] Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
    Heerspink, Hiddo J. L.
    Parving, Hans-Henrik
    Andress, Dennis L.
    Bakris, George
    Correa-Rotter, Ricardo
    Hou, Fan-Fan
    Kitzman, Dalane W.
    Kohan, Donald
    Makino, Hirofumi
    McMurray, John J. V.
    Melnick, Joel Z.
    Miller, Michael G.
    Pergola, Pablo E.
    Perkovic, Vlado
    Tobe, Sheldon
    Yi, Tingting
    Wigderson, Melissa
    de Zeeuw, Dick
    LANCET, 2019, 393 (10184): : 1937 - 1947
  • [22] Exenatide.: Treatment of type 2 diabetes GLP-1 receptor agonist
    McIntyre, JA
    Bayés, M
    DRUGS OF THE FUTURE, 2004, 29 (01) : 23 - 31
  • [23] Metabolic improvement during short-term treatment with a GLP-1 receptor agonist does not improve cardiac diastolic function in patients type 2 diabetes: a randomized double-blind placebo-controlled trial
    Bojer, A. S.
    Soerensen, M. S.
    Bjerre, J.
    Gaede, P.
    Vejlstrup, N.
    Madsen, P. L.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2619 - 2619
  • [24] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
    Rosenstock, Julio
    Frias, Juan
    Jastreboff, Ania M.
    Du, Yu
    Lou, Jitong
    Gurbuz, Sirel
    Thomas, Melissa K.
    Hartman, Mark L.
    Haupt, Axel
    Milicevic, Zvonko
    Coskun, Tamer
    LANCET, 2023, 402 (10401): : 529 - 544
  • [25] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
    Gerstein, Hertzel C.
    Colhoun, Helen M.
    Dagenais, Gilles R.
    Diaz, Rafael
    Lakshmanan, Mark
    Pais, Prem
    Probstfield, Jeffrey
    Riesmeyer, Jeffrey S.
    Riddle, Matthew C.
    Ryden, Lars
    Xavier, Denis
    Atisso, Charles Messan
    Dyal, Leanne
    Hall, Stephanie
    Rao-Melacini, Purnima
    Wong, Gloria
    Avezum, Alvaro
    Basile, Jan
    Chung, Namsik
    Conget, Ignacio
    Cushman, William C.
    Franek, Edward
    Hancu, Nicolae
    Hanefeld, Markolf
    Holt, Shaun
    Jansky, Petr
    Keltai, Matyas
    Lanas, Fernando
    Leiter, Lawrence A.
    Lopez-Jaramillo, Patricio
    Cardona Munoz, Ernesto German
    Pirags, Valdis
    Pogosova, Nana
    Raubenheimer, Peter J.
    Shaw, Jonathan E.
    Sheu, Wayne H-H
    Temelkova-Kurktschiev, Theodora
    LANCET, 2019, 394 (10193): : 121 - 130
  • [26] Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
    Hartemann, Agnes
    Bensimon, Gilbert
    Payan, Christine A.
    Jacqueminet, Sophie
    Bourron, Olivier
    Nicolas, Nathalie
    Fonfrede, Michele
    Rosenzwajg, Michelle
    Bernard, Claude
    Klatzmann, David
    LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (04): : 295 - 305
  • [27] The effect of the GLP-1 receptor agonist liraglutide on heart rate and heart rate variability in patients with type-2 diabetes: a randomized double-blind placebo-controlled cross over study
    Kumarathurai, P.
    Anholm, C.
    Larsen, B. S.
    Olsen, R. H.
    Madsbad, S.
    Kristiansen, O.
    Nielsen, O. W.
    Haugaard, S. B.
    Sajadieh, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1094 - 1095
  • [28] EFFECT OF SITAGLIPTIN ON POSTPRANDIAL GLUCAGON AND GLP-1 LEVELS IN PATIENTS WITH TYPE 1 DIABETES: INVESTIGATOR-INITIATED, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Garg, Satish K.
    Moser, Emily G.
    Bode, Bruce W.
    Klaff, Leslie J.
    Hiatt, William R.
    Beatson, Christie
    Snell-Bergeon, Janet K.
    ENDOCRINE PRACTICE, 2013, 19 (01) : 19 - 28
  • [29] Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
    Sennik, Devesh
    Ahmed, Fahad
    Russell-Jones, David
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (01) : 15 - 26
  • [30] Creatine in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Gualano, Bruno
    Painneli, Vitor De Salles
    Roschel, Hamilton
    Artioli, Guilherme Giannini
    Neves, Manoel, Jr.
    De Sa Pinto, Ana Lucia
    Rossi Da Silva, Maria Elizabeth
    Cunha, Maria Rosaria
    Garcia Otaduy, Maria Concepcion
    Leite, Claudia Da Costa
    Ferreira, Julio Cesar
    Pereira, Rosa Maria
    Brum, Patricia Chakur
    Bonfa, Eloisa
    Lancha, Antonio Herbert, Jr.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2011, 43 (05): : 770 - 778
12345